VictorWViewegR.Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. J Clin Psychiatry2002;63 (Suppl 9):18–24.
2.
TanHLHouCJLauerMR, and others. Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med1995;122:701–14.
3.
GlassmanAH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry2002;63(Suppl 9):12–6.
4.
CzekallaJBeasleyCMDeelvaMA, and others. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry2001;62:191–8.
5.
CzekallaJKollack-WalkerSBeasleyCM. Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics. J Clin Psychiatry2001;62 (Suppl 22):35–40.
6.
GuptaNMalhotraP.Olanzapine: A proarrhythmic drug? [letter]. Can J Psychiatry2002;47:683–4.
7.
BouchardRHDemersMFSimoneauI, and others. Atypical antipsychotics and cardiovascular risk in schizophrenic patients [letter]. J Clin Psychopharmacol2001;21:110–11.
